Drug Shortage Report for DALACIN C PHOSPHATE

Last updated on 2023-08-26 History
Report ID 134283
Drug Identification Number 00260436
Brand name DALACIN C PHOSPHATE
Common or Proper name Dalacin C Phosphate
Company Name PFIZER CANADA ULC
Market Status MARKETED
Active Ingredient(s) CLINDAMYCIN
Strength(s) 150MG
Dosage form(s) SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS
Packaging size 25x6mL vial
ATC code J01FF
ATC description MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2021-06-14
Estimated end date
Actual end date 2023-08-25
Shortage status Resolved
Updated date 2023-08-26
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 17300 TRANS-CANADA HIGHWAY
KIRKLAND, QUEBEC
CANADA H9J 2M5
Company contact information Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v15 2023-08-26 English Compare
v14 2023-08-25 French Compare
v13 2023-08-25 English Compare
v12 2023-04-27 French Compare
v11 2023-04-27 English Compare
v10 2023-03-16 French Compare
v9 2023-03-16 English Compare
v8 2021-12-10 French Compare
v7 2021-12-10 English Compare
v6 2021-06-15 French Compare
v5 2021-06-15 English Compare
v4 2021-06-02 French Compare
v3 2021-06-02 English Compare
v2 2021-02-17 French Compare
v1 2021-02-17 English Compare

Showing 1 to 15 of 15